scholarly journals Possible algorithms for determining adverse reactions caused by food supplements in Romania

2021 ◽  
Vol 2 (4) ◽  
pp. 4-27
Author(s):  
Irina Mihaela MATRAN ◽  
Daniela Lucia MUNTEAN ◽  
Cristina NICULAS ◽  
Roxana Maria MARTIN-HADMAS ◽  
Monica TARCEA
Keyword(s):  
Side Effects ◽  
Adverse Reactions ◽  
Aloe Vera ◽  
Food Supplements ◽  
Mentha Piperita ◽  
Plant Resources ◽  
Matricaria Recutita ◽  
Gastrointestinal Side Effects ◽  
Media Channels ◽  
Dermatological Side Effects

Introduction. The advertising of food supplements on various media channels or in specialty stores with natural products and other places, as well as the lack of informative and educational programs for the population upon side effects and the interaction of food supplements with food and drugs, have led to the development of uncontrolled marketing of these products. Material and methods. PubMed, ResearchGate and EUR-Lex databases were analyzed during 2015-2021, based on search criteria based on: adverse reactions, ingredient new food, food supplements, algorithms. Results. Certain dietary supplements can cause multiple side effects, such as: impaired platelet function by decreased platelet aggregation, gastrointestinal side effects (diarrhea, vomiting), decreased wound healing/epithelialization, bacterial or fungal sepsis, most common in patients older. Herbal resources such as Aloe vera, Matricaria recutita, Taraxacum officinale and others, can cause dermatological side effects and inhibit the elimination of dermatological drugs metabolised by cytochrome P-450 (e.g. terbinafine). Matricaria recutita, Allium sativum, Mentha piperita L. and others, inhibit the enzyme CYP2C9. Another enzyme with a role in the metabolism of dermatological drugs and which is inhibited by plant resources is CYP3A4. Conclusions. It is imperative to legislate the reporting of adverse reactions caused by food supplements, including their interaction with food or drugs.

scholarly journals Nightmare and Abnormal Dreams: Rare Side Effects of Metformin?

2018 ◽  
Vol 2018 ◽  
pp. 1-3 ◽  
Author(s):  
Theo Audi Yanto ◽  
Ian Huang ◽  
Felicia Nathania Kosasih ◽  
Nata Pratama Hardjo Lugito
Keyword(s):  
Side Effects ◽  
Extended Release ◽  
Adverse Reactions ◽  
Antidiabetic Agent ◽  
Probability Scale ◽  
Case Presentation ◽  
Gastrointestinal Side Effects ◽  
History Of ◽  
Negative Feelings ◽  
Unpleasant Experience

Background. Metformin is widely known as an antidiabetic agent which has significant gastrointestinal side effects, but nightmares and abnormal dreams as its adverse reactions are not well reported. Case Presentation. Herein we present a case of 56-year-old male patient with no known history of recurrent nightmares and sleep disorder, experiencing nightmare and abnormal dreams directly after consumption of 750 mg extended release metformin. He reported his dream as an unpleasant experience which awakened him at night with negative feelings. The nightmare only lasted for a night, but his dreams every night thereafter seemed abnormal. The dreams were vivid and indescribable. The disappearance and occurrence of abnormal dreams ensued soon after the drug was discontinued and rechallenged. The case was assessed using Naranjo Adverse Drug Reaction (ADR) probability scale and resulted as probable causality. Conclusion. Metformin might be the underlying cause of nightmare and abnormal dreams in this patient. More studies are needed to confirm the association and causality of this findings.

Gastrointestinal Side Effects with Erythromycin Preparations

1987 ◽  
Vol 21 (9) ◽  
pp. 734-738 ◽  
Author(s):  
Barry L. Carter ◽  
Jerold C. Woodhead ◽  
Katherine J. Cole ◽  
Gary Milavetz
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Adverse Reactions ◽  
Enteric Coated Tablet ◽  
High Incidence ◽  
Coated Tablet ◽  
Gastrointestinal Side Effects ◽  
Enteric Coated

This study was designed to determine the incidence and severity of gastrointestinal (GI) side effects in patients taking erythromycin. More patients complained of GI side effects with the enteric-coated tablet (70.8 percent) than with the stearate (51.4 percent) or the ethylsuccinate (48.9 percent) salts. The enteric-coated tablet was associated with a higher incidence of individual adverse reactions; more patients discontinued it because of adverse GI effects. These data demonstrate a high incidence of GI side effects to erythromycin. Additionally, GI side-effect incidence appears to be higher with the enteric-coated tablet.

scholarly journals Lactobacillus reuteri Alleviates Gastrointestinal Toxicity of Rituximab by Regulating the Proinflammatory T Cells in vivo

2021 ◽  
Vol 12 ◽  
Author(s):  
Binyan Zhao ◽  
Bailing Zhou ◽  
Chunyan Dong ◽  
Rui Zhang ◽  
Daoyuan Xie ◽  
...  
Keyword(s):  
Side Effects ◽  
Intestinal Microbiota ◽  
Adverse Reactions ◽  
Lactobacillus Reuteri ◽  
Intestinal Inflammation ◽  
Mucosal Damage ◽  
Intragastric Administration ◽  
Inflammatory Factor ◽  
Gastrointestinal Side Effects

Rituximab (RTX) is a widely used anticancer drug with gastrointestinal side effects, such as nausea, vomiting, and diarrhea. The reason for these side effects is still poorly understood. Previous studies have reported that the intestinal microbiota is associated with the occurrence of disease and the therapeutic effect of drugs. In this study, we observed mucosal damage, inflammatory cell infiltration and increased intestinal inflammatory factor expression in RTX-treated mice. RTX also changed the diversity of the intestinal microbiota in mice, and decreased abundance of Lactobacillus reuteri was observed in RTX-treated mice. Further experiments revealed that intragastric administration of L. reuteri in RTX-treated mice attenuated the intestinal inflammatory response induced by RTX and regulated the proportion of helper T (Th) cells. In conclusion, our data characterize the effect of the intestinal microbiota on RTX-induced intestinal inflammation, suggesting that modifying the gut microbiota may represent a positive strategy for managing adverse reactions.

Cutaneous ulcers following hydroxyurea therapy

Phlebologie ◽  
2004 ◽  
Vol 33 (06) ◽  
pp. 202-205 ◽  
Author(s):  
K. Hartmann ◽  
S. Nagel ◽  
T. Erichsen ◽  
E. Rabe ◽  
K. H. Grips ◽  
...  
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Antineoplastic Agent ◽  
Limited Time ◽  
Myeloproliferative Diseases ◽  
Dermatological Side Effects ◽  
Chronic Myeloproliferative Diseases ◽  
Hydroxyurea Therapy

SummaryHydroxyurea (HU) is usually a well tolerated antineoplastic agent and is commonly used in the treatment of chronic myeloproliferative diseases. Dermatological side effects are frequently seen in patients receiving longterm HU therapy. Cutaneous ulcers have been reported occasionally.We report on four patients with cutaneous ulcers whilst on long-term hydroxyurea therapy for myeloproliferative diseases. In all patients we were able to reduce the dose, or stop HU altogether and their ulcers markedly improved. Our observations suggest that cutaneous ulcers should be considered as possible side effect of long-term HU therapy and healing of the ulcers can be achieved not only by cessation of the HU treatment, but also by reducing the dose of hydroxyurea for a limited time.

Sulfinpyrazone or Acetylsalicylic Acid to Prevent Postoperative Thrombus Formation in Arteriovenous Fistulas of Haemodialysis Patients

1979 ◽  
Author(s):  
F Albert ◽  
U Schmidt
Keyword(s):  
Side Effects ◽  
Acetylsalicylic Acid ◽  
Thrombus Formation ◽  
Significant Inhibition ◽  
High Rate ◽  
Controlled Clinical Trial ◽  
Arteriovenous Fistulas ◽  
Arteriovenous Shunts ◽  
Gastrointestinal Side Effects ◽  
Antithrombotic Efficacy

The effect of sulfinpyrazone (200 mg three times a day) and acetylsalicylic acid (500 mg three times a day) on the incidence of thrombosis of arteriovenous shunts was investigated in a controlled clinical trial. In 36 patients with chronic renal failure scheduled to begin haemodialysis the same operating team constructed a subcutaneous fistula in the distal forearm. During the first six weeks after the operation the antithrombotic efficacy proved to be good for both substances. No differences of thrombotic events between the two treatment groups were statistically significant. But in contrast to acetylsalicylic acid sulfinpyrazone made no significant inhibition of platelet - aggregation; sulfinpyrazone probably will prevent the clot formation by prolonging the shortened platelet survival in uraemic patients. In a high rate of patients given acetylsalicylic acid (10 out of 17) there were local bleeding and gastrointestinal side effects. In consequence we should prefer sulfinpyrazone, because in the sulfinpyrazone group side effects were minimal and in none patient withdrawal from the study was necessitated.

scholarly journals The Safety of COVID-19 Vaccinations—We Should Rethink the Policy

Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 693
Author(s):  
Harald Walach ◽  
Rainer J. Klement ◽  
Wouter Aukema
Keyword(s):  
Side Effects ◽  
Confidence Interval ◽  
Field Study ◽  
Adverse Reactions ◽  
Safety Data ◽  
European Medicines Agency ◽  
Point Estimate ◽  
Drug Reactions ◽  
Vaccination Policy ◽  
Risks And Benefits

Background: COVID-19 vaccines have had expedited reviews without sufficient safety data. We wanted to compare risks and benefits. Method: We calculated the number needed to vaccinate (NNTV) from a large Israeli field study to prevent one death. We accessed the Adverse Drug Reactions (ADR) database of the European Medicines Agency and of the Dutch National Register (lareb.nl) to extract the number of cases reporting severe side effects and the number of cases with fatal side effects. Result: The NNTV is between 200–700 to prevent one case of COVID-19 for the mRNA vaccine marketed by Pfizer, while the NNTV to prevent one death is between 9000 and 50,000 (95% confidence interval), with 16,000 as a point estimate. The number of cases experiencing adverse reactions has been reported to be 700 per 100,000 vaccinations. Currently, we see 16 serious side effects per 100,000 vaccinations, and the number of fatal side effects is at 4.11/100,000 vaccinations. For three deaths prevented by vaccination we have to accept two inflicted by vaccination. Conclusions: This lack of clear benefit should cause governments to rethink their vaccination policy.

scholarly journals DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1046
Author(s):  
Gerardo Casucci ◽  
Domenico Acanfora
Keyword(s):  
Side Effects ◽  
Disseminated Intravascular Coagulation ◽  
Adverse Reactions ◽  
Thrombus Formation ◽  
European Countries ◽  
European Medicines Agency ◽  
Safety Committee ◽  
Vectored Vaccine ◽  
Short Time ◽  
Prompt Diagnosis

In recent weeks, adverse reactions have been reported after administration of Oxford–AstraZeneca chimpanzee adenovirus vectored vaccine ChAdOx1 nCoV-19 (AZD1222), in particular thrombus formation, which has led several European Countries to discontinue administration of this vaccine. On March 8, 2021, the European Medicines Agency Safety Committee did not confirm this probable association. We report the case of a patient who developed disseminated intravascular coagulation after the first dose of Oxford-Astra Zeneca vaccine, which resolved in a few days with the administration of dexamethasone and enoxaparin. This work demonstrates the safety of the Oxford-Astra Zeneca vaccine and that any development of side effects can be easily managed with a prompt diagnosis and in a short time with a few commonly used drugs.

Sign in / Sign up

Export Citation Format

Share Document